Our Pipeline

Our Pipeline

Among our current portfolio of intellectual property we have an extensive collection of state-of-the-art drug delivery agents ready for clinical application and licensing. Overall NYCNMR has a portfolio of over 30 drug/gene delivery systems.

The following nanotechnology platforms are operational

• Liposomal Delivery and Targeting Systems (Both Natural and Synthetic)
• Micelle Delivery and Targeting Systems
• Notched Vessels for controlled released via enzymatic or energy based triggering
• Nano Cages, Cationic Strings, Graphene, Clay and Polymeric Systems
• Fast and High Efficient Cellular Transfection/Delivery Systems for Drugs, Genetic Materials including Plasmids.
• BBB/BNB models and efficient transport systems
• PDT Compounds and Treatment including 12 licensed IP Technologies
• Advanced Transdermal Systems
• Nanoparticle Synthesis
• Non-Toxic Quantum Dots
• Vaccine Development Platforms
• Drug Delivery Platforms in all routes including Intranasal
• Imaging and Contrast Agents
• EM Shielding and Scattering Technologies (Mostly Military Use)
• Targeted Delivery of Drugs to Specific Cells, Tissues and Organs
• Transit of Theranostics Across the Blood Brain Barrier
• Gene Therapy of Cancer, HIV Infections, Asthma, and COPD